Technical Analysis for GPCR - Structure Therapeutics Inc.

Grade Last Price % Change Price Change
A 50.42 34.56% 12.95
GPCR closed up 34.56 percent on Friday, September 29, 2023, on 13.52 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Up

Date Alert Name Type % Chg
Gilligan's Island Sell Setup Bearish Swing Setup 0.00%
New 52 Week Closing High Bullish 0.00%
New Uptrend Bullish 0.00%
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
New 52 Week High Strength 0.00%
Parabolic Rise Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 11 hours ago
Gapped Up (Full) about 13 hours ago
Rose Above Previous Day's High about 13 hours ago
New 52 Week High about 13 hours ago
Rose Above Upper Bollinger Band about 13 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Structure Therapeutics Inc. Description

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Biology Molecular Biology Obesity Pulmonary Arterial Hypertension Signal Transduction Chronic Disease Diabetes Mellitus Idiopathic Pulmonary Fibrosis Biochemistry Glucagon Receptor

Is GPCR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 65.51
52 Week Low 20.8001
Average Volume 736,172
200-Day Moving Average 0.00
50-Day Moving Average 31.57
20-Day Moving Average 33.01
10-Day Moving Average 36.48
Average True Range 3.99
RSI (14) 83.33
ADX 26.92
+DI 63.35
-DI 6.71
Chandelier Exit (Long, 3 ATRs) 53.53
Chandelier Exit (Short, 3 ATRs) 39.23
Upper Bollinger Bands 42.90
Lower Bollinger Band 23.12
Percent B (%b) 1.38
BandWidth 59.91
MACD Line 2.73
MACD Signal Line 1.34
MACD Histogram 1.3895
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 75.86
Resistance 3 (R3) 78.06 71.79 71.62
Resistance 2 (R2) 71.79 65.31 70.68 70.21
Resistance 1 (R1) 61.10 61.31 57.97 58.90 68.79
Pivot Point 54.83 54.83 53.26 53.73 54.83
Support 1 (S1) 44.14 48.35 41.01 41.94 32.05
Support 2 (S2) 37.87 44.35 36.77 30.63
Support 3 (S3) 27.18 37.87 29.22
Support 4 (S4) 24.98